The worldwide impact of vaccination on the control and protection of viral hepatitis B (Q83078584)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21195368%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

The worldwide impact of vaccination on the control and protection of viral hepatitis B (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21195368%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

1 reference

Luisa Romano'

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21195368%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Sara Paladini

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21195368%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Pierre Van Damme

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21195368%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Alessandro R Zanetti

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21195368%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21195368%20AND%20SRC:MED&resulttype=core&format=json

Digestive and Liver Disease

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21195368%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

43 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21195368%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

S2-7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21195368%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis B virus infection

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

A mathematical model to estimate global hepatitis B disease burden and vaccination impact.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Human hepatitis B vaccine from recombinant yeast

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Use of a new combined vaccine in pediatric practices

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

The use of combination vaccines has improved timeliness of vaccination in children

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine).

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

The global impact of vaccination against hepatitis B: a historical overview

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Mass vaccination against hepatitis B in infants in Italy

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Vaccination against hepatitis B: the Italian strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Persistence of specific antibodies after hepatitis B vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Long-term protection of hepatitis B vaccine: lessons from Alaskan experience after 15 years

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Are booster immunisations needed for lifelong hepatitis B immunity?

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Hepatitis B vaccination: to boost or not to boost?

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Hepatitis B vaccination and the risk of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Safety of immunization and adverse events following vaccination against hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Does the hepatitis B vaccine cause multiple sclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Long-term protection against carriage of hepatitis B virus after infant vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Impact of the Expanded Program of Immunization against hepatitis B infection in school children in Malaysia

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Near elimination of hepatitis B virus infections among Hawaii elementary school children after universal infant hepatitis B vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Acute hepatitis B 14 years after the implementation of universal vaccination in Italy: areas of improvement and emerging challenges

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Impact of hepatitis B vaccination in a highly endemic area of south Italy and long-term duration of anti-HBs antibody in two cohorts of vaccinated individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Chronic hepatitis D: a vanishing Disease? An Italian multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Hepatitis B variant in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Vaccine-induced escape mutant of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

No increase in prevalence of hepatitis B surface antigen mutant in a population of children and adolescents who were fully covered by universal infant immunization.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960685-8

7 January 2021

10.1016/S1590-8658(10)60685-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21195368%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference